Results 41 to 50 of about 6,465,161 (268)

The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

BMC Cancer
Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies.
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria   +13 more
doaj   +1 more source

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

Breast, 2021
Background: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of ...
I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu   +6 more
doaj   +1 more source

Progression-free survival according to BMI status at baseline.

, 2018
Progression-free survival according to BMI status at baseline.
Ji Kon Ryu (481706), Jun Hyuk Son (2921766), Woo Hyun Paik (481705), Jae Woo Lee (2072779), Young Hoon Choi (2725033), Sang Hyub Lee (5047862), Yong-Tae Kim (249037), Jinwoo Kang (5047865), Jin Ho Choi (3852334)   +8 more
core   +1 more source

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +21 more
wiley   +1 more source

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.
Chengchen Wang, Hongyi Fu, Feng Wang
doaj   +1 more source

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BMC Cancer, 2021
Background An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms.
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen   +5 more
doaj   +1 more source

Progression-free survival curve of the 13 patients.

, 2018
The 5-year progression-free survival rate was 63.5%.
Yifei Wang (95207), Tao Ji (1313499), Wei Guo (86150), Zhongyan Chen (1883233), Ran Wei (295560)   +4 more
core   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source

Progression-free survival (PFS) during erlotinib therapy (with 95% CI).

, 2019
Progression-free survival (PFS) during erlotinib therapy (with 95% CI).
Tim Van den Wyngaert (4330615), Paul Germonpré (6580541)   +1 more
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source